# A Rollover Protocol for Subjects Previously Treated With AGS-003

Source: https://onco.cc/trials/nct01482949/  
OnCo record `nct01482949` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rocapuldencel-T run by Argos Therapeutics, terminated.

## Summary

A Rollover Protocol for Subjects Previously Treated With AGS-003 is a phase 2 interventional study registered as NCT01482949 by Argos Therapeutics, with 2 participants enrolled, started 2011-09. Conditions recorded: Renal Cell Carcinoma. Interventions recorded: AGS-003.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01482949
- Phase: 2
- Setting: A Rollover Phase II Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects With Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006
- Sponsor: Argos Therapeutics
- Enrolled: 2

## Sources

- ClinicalTrials.gov NCT01482949: https://clinicaltrials.gov/study/NCT01482949

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Rocapuldencel-T](https://onco.cc/drugs/rocapuldencel-t/)
- companies: [Argos Therapeutics](https://onco.cc/companies/argos-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct01482949.json